RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
This is a single-arm exploratory study to explore the effect of RC48 in HER2-positive
neoadjuvant therapy and evaluate the non-inferiority of RC48 by comparing the latest reported
data of T-DM1 in neoadjuvant therapy.